Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinum-based chemotherapy

Clinical Lung Cancer

Volumn 4, Issue 3, 2002, Pages 168-173

  Muñoz, Alberto ^a   Rubio, Itziar ^a   Mañé, Juan Manuel ^a   Ferreiro, Josefa ^a   Fernández, Ricardo ^a   Abón, Guadalupe ^a   López de Argumedo, Gonzalo ^a   Fuente, Natalia ^a   Barceló, José Ramón ^a   López Vivanco, Guillermo ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Neutropenia; Nonplatinum; Second line; Taxane; Vinca alkaloid

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LACTATE DEHYDROGENASE; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; PACLITAXEL; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAVASATION; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUID RETENTION; HEART ARRHYTHMIA; HICCUP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SEPSIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING;

EID: 0036868675     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2002.n.024     Document Type: Article

References (29)

1. Carney DN. Non-small cell lung cancer: slow but definite progress. Semin Oncol 1996; 23(suppl 16):5-6.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
3. Comer AM, Goa KL. Docetaxel: a review of its use in non-small cell lung cancer. Drugs Aging 2000; 17:53-80.
4. Fossella FV, Lee JS, Berille J, et al. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22:22-29.
5. Miller V, Kris M. Vinorelbine for the treatment of advanced non-small cell lung cancer. Med Lett Drugs Ther 1995; 37:72-73.
6. Kourousis C, Androulakis N, Kakolyris S, et al. First-tine treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine. Cancer 1998; 83:2083-2090.
7. Bennouna J, Monnier A, Rivi A, et al. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 2000; 36:1107-1112.
8. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:1346-1350.
9. O'Rourke M, Garfield D, P. E. Phase II trial of Taxotere (T) and Navelbine (N) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 1999; 18:519a (Abstract #1999).
10. Balana C, Barnadas A, Martin C. ea. A phase II study of sequence-dependent docetaxel (D)/vinorelbine (V) DNA damage-induced apoptosis in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999; 18:463a (Abstract #1786).
11. Johnston E, Crawford J, Garst A, et al. Phase I trial of weekly docetaxel (D) and vinorelbine (V) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999; 18:476a (Abstract #1838).
12. Huisman C, Smit EF, Giaccone G, et al. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18:3722-3730.
13. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
14. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
15. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
16. Simon R. Design and analysis of clinical trials. In: DeVita VT, Hellman S, Rosemberg, SA eds. Cancer Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997:513-528.
17. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
18. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15:2996-3018.
19. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer (NSCLC). N Engl J Med 2002; 346:92-98
20. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III Study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18.
21. Bunn PA, Jr., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-1100.
22. Spiridonidis CH, Laufman LR, Carman L, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 2001; 12:89-94.
23. Androulakis N, Papadakis E, Bania E, et al. Second line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II trial. Proc Am Soc Clin Oncol 1999; 18:494a (Abstract #1907).
24. Leu KM, Kim KM, Larson M, et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy, Lung Cancer 2001; 34:105-113.
25. Crawford J, Garst J, Kelley M, et al. Phase II trial of weekly docetaxel and vinorelbine in patients with relapsed non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:245b (Abstract #2730).
26. Papadimitrakopoulou V, Lozada J, Henderson T, et al. A phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second-line therapy. Proc Am Soc Clin Oncol 2001; 20:2591b (Abstract #2789).
27. Morales S, Milla A, Madronal C. Preliminary results of a phase II study of docetaxel in combination with vinorelbine as second line treatment in non-small-cell lung cancer (NSCLC). An Oncopaz and Associated Hospitals study, Proc Am Soc Clin Oncol 2001; 20:2441b (Abstract #2728).
28. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-1872.
29. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106:861-865.